Lactoferrin: A Natural Glycoprotein Involved in Iron and Inflammatory Homeostasis.
Rosa L, Cutone A, Lepanto MS, Paesano R, Valenti P. · 2017
Read Lactoferrin: A Natural Glycoprotein Involved in Iron and Inflammatory Homeostasis. by Rosa L, Cutone A, Lepanto MS, Paesano R, Valenti P. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5618634.txt.
Introduction
Rosa and co-authors review lactoferrin in the International Journal of Molecular Sciences. Lactoferrin is an iron-binding protein in milk, tears, and other secretions. Neutrophils release it as well. It stands guard at the body's surfaces.
The review ties the protein to two linked balances. Iron control and inflammation control rise and fall together. Lactoferrin starves bacteria of iron and blocks their docking. It also curbs interleukin-6 inside inflamed cells. That shift raises ferroportin, the iron exporter. Iron then moves out of overloaded cells into blood. The effect can ease anemia of inflammation. Trial results in pregnant women showed lower IL-6 and better blood counts. Bovine lactoferrin even helped guard against preterm delivery. Readers get one protein cast as a traffic cop for iron.
Catalog record
| CREATOR | Rosa L, Cutone A, Lepanto MS, Paesano R, Valenti P. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 95 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Lactoferrin: A Natural Glycoprotein Involved in Iron and Inflammatory Homeostasis By Luigi Rosa, Antimo Cutone, Maria Stefania Lepanto, Rosalba Paesano, Piera Valenti Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms18091985 ABSTRACT Human lactoferrin (hLf), an iron-binding multifunctional cationic glycoprotein secreted by exocrine glands and by neutrophils, is a key element of host defenses. HLf and bovine Lf (bLf), possessing high sequence homology and identical functions, inhibit bacterial growth and biofilm dependently from iron binding ability while, independently, bacterial adhesion to and the entry into cells. In infected/inflamed host cells, bLf exerts an anti-inflammatory activity against interleukin-6 (IL-6), thus up-regulating ferroportin (Fpn) and transferrin receptor 1 (TfR1) and down-regulating ferritin (Ftn), pivotal actors of iron and inflammatory homeostasis (IIH). Consequently, bLf inhibits intracellular iron overload, an unsafe condition enhancing in vivo susceptibility to infections, as well as anemia of inflammation (AI), re-establishing IIH. In pregnant women, affected by AI, bLf oral administration decreases IL-6 and increases hematological parameters. This surprising effect is unrelated to iron supplementation by bLf (80 μg instead of 1–2 mg/day), but to its role on IIH. AI is unrelated to the lack of iron, but to iron delocalization: cellular/tissue overload and blood deficiency. BLf cures AI by restoring iron from cells to blood through Fpn up-expression. Indeed, anti-inflammatory activity of oral and intravaginal bLf prevents preterm delivery. Promising bLf treatments can prevent/cure transitory inflammation/anemia/oral pathologies in athletes. 1. IRON AND ITS HOMEOSTASIS Iron, an essential element for cell growth and proliferation, is a component of fundamental processes such as DNA replication and energy production. However, iron can also be toxic when present in excess for its capacity to donate electrons to oxygen, thus causing the generation of reactive oxygen species (ROS), such as superoxide anions and hydroxyl radicals [1]. ROS are known to cause tissue injury and organ failure by damaging a number of cellular components, including DNA, proteins and membrane lipids. This dichotomy of iron, able to gain and loss electrons, has led to the evolution of tight controls on iron uptake to minimize iron deficiency, as well as iron excess. Sophisticated strategies have been developed both to avoid iron in free available toxic form and to maintain the correct iron balance/ratio between tissues/secretions and blood, defined as iron homeostasis. In humans, total body iron, about 3 g for women and 4 g for men, is distributed in two main forms: hemic-iron, mostly found in the hemoglobin, myoglobin and cytochromes (2–2.7 g), and non-hemic-iron, a cofactor of several enzymes. Dietary iron is absorbed in the proximal small intestine (duodenum). In developed countries, about 15 mg of iron per day are provided by a balanced diet, but only ~10% (1–2 mg) is absorbed, due to its extremely poor bio-availability. Interestingly, 20 mg of iron per day, used for the de novo synthesis of heme, derive from senescent erythrocyte lyses by macrophages. The iron recovered from hemoglobin of senescent erythrocytes is the largest iron source in the reticuloendothelial system. Finally, every day, a few milligrams of iron are regained from storage in hepatocytes and macrophages. In human cells, the required iron is guaranteed by transferrin (Tf)-bound iron, which is imported into cells through receptor-mediated endocytosis. In the endosome, Tf-bound iron is released as ferrous ion, which is translocated via divalent metal transporter 1 (DMT1) into cytoplasm where it is sequestered by ferritin (Ftn). Ftn, the major iron storage protein, composed by 24 subunits, possesses ferroxidase activity and a large cavity where up to 4500 ferric ions, as oxy-hydroxide micelles, are sequestered. The release of iron from this protein to cytoplasm occurs after reduction of ferric to ferrous ions. Then, ferrous ions are exported into plasma by ferroportin (Fpn), the only known mammalian iron exporter found on the cytoplasmic membrane of enterocytes, hepatocytes, macrophages and placental cells [2]. Of note, Fpn acts in partnership with two ferroxidases: hephaestin (Heph), found in epithelial cells, and ceruloplasmin (Cp), in macrophages [3]. Both ferroxidases convert ferrous into ferric ions in order to allow their binding to Tf in the blood. Fpn is an important actor of iron homeostasis, regulated by multiple factors. In particular, Fpn is down-regulated by the pro-inflammatory cytokine interleukin-6 (IL-6) [4,5] and by hepcidin, another pivotal actor, which regulates iron homeostasis through the binding, internalization and degradation of Fpn [6]. The bioactive hepcidin, a cationic peptide hormone of 25 amino acids mainly synthesized by hepatocytes, derives from the proteolytic cleavage of an 84-amino acid precursor, and it is secreted in urine [7,8] and plasma [9]. As Fpn, hepcidin is controlled by several factors. In particular, it is transcriptionally feedback-regulated by iron stores [10]. This mechanism involves multiple pathways through which hepatocytes directly sense systemic iron levels [10,11]. Hepcidin synthesis is also up-regulated by pro-inflammatory cytokines, such as IL-6, IL-1α and IL-1β [12,13,14,15]. The Fpn degradation caused by the binding with hepcidin or its down-regulation by IL-6 provokes a significant decrease of iron export from cells into plasma. Consequently, at the cellular level, iron overload in the host cells including enterocytes and macrophages is established, while at the systemic level, iron deficiency (ID), ID anemia (IDA) and anemia of inflammation (AI) have been found [16,17]. In ID without anemia, total serum iron (TSI) concentration and serum Ftn (sFtn) are very low, while hemoglobin (Hb) levels remain normal. ID may be classified according to sFtn and TSI concentrations (<24 ng/mL and <30 mg/dL, respectively) as mild (sFtn = 12–24 ng/mL) or severe ID (sFtn < 12 ng/mL). In IDA, the iron stores are low or absent, resulting in severe low hemoglobin (Hb) and red blood cell (RBC) levels. IDA is usually classified in line with the number of RBCs (<4 × 106 cells/mL) and Hb concentration (<11 g/dL,) as mild (Hb 7–10.9 g/dL) or severe IDA (Hb < 7 g/dL). In AI, in addition to the low hematological parameters, normal-to-elevated sFtn and high levels of IL-6 and other pro-inflammatory cytokines are observed. ID, IDA and AI are the most widespread iron disorders with over 30% of the world’s population affected by anemia, with the cause of anemia primarily due to iron deficiency [18]. In particular, in developing countries, the high amounts of polyphenols (tannins) and phytates, present in cereal- and tuber-based diets, increase ID and IDA incidence due to their influence on iron absorption. The most common intervention programs for ID and IDA are based on the classical preconception that oral iron administration or the consumption of iron-rich foods increases hematological parameters, thus reducing the prevalence of anemia. However, although most of these programs designed by governments and international agencies are easy to perform at low cost, they are ineffective in preventing and curing ID and IDA. Several studies highlighted how ferrous iron supplementation often fails to restore iron homeostasis disorders in patients suffering from ID and IDA, causing frequent adverse effects, such as gastrointestinal discomfort, nausea, vomiting, diarrhea and constipation [19,20,21,22,23]. Moreover, in vivo studies in rats fed with an iron-enriched diet showed a higher production of ROS [24] and a more severe progression of the colitis inflammatory status [25]. AI, the most severe iron homeostasis disorder, is difficult to prevent and cure because it is associated with high levels of IL-6, which in turn induce the deregulation of